



Shasta County
**Health & Human
Services Agency** | Public Health
Branch

COVID-19 Health Update #30

January 26, 2022

Please distribute to all providers in the facility

Go to www.ShastaReady.org and click “Medical Professionals” for an electronic version of this Health Update

Authorization of Paxlovid and Molnupiravir for Oral treatment of Mild-to-Moderate COVID-19 in Shasta County

In late December 2021, FDA authorized two new, oral antiviral medications for the early treatment of outpatients with mild-to-moderate COVID-19 who are at high risk for progression to severe disease.

The California Department of Public Health (CDPH) has issued health advisories with information and guidance on use of both [Paxlovid](#) (Ritonavir-boosted Nirmatrelvir) and [Molnupiravir](#).

Supply of these products is currently extremely limited and available only through a few designated [locations](#). CDPH has issued clinical criteria in a [Provider Letter](#) to prioritize the doses that are available.

Shasta County HHS Public Health is committed to ensuring ethical distribution of this scarce resource. As the manufacturing of these therapeutic agents ramps up over the next several months and many more treatment courses become available, SCPH will work to expand pharmacy access to additional locations, including more community-based pharmacies.

For non-hospitalized patients with mild to moderate COVID-19 who are at high risk of disease progression, the [NIH Panel](#) recommends using one of the following therapeutics (listed in order of preference): 1. Paxlovid (oral tx) 2. Sotrovimab (IV mAb tx) 3. Remdesivir (IV once daily for three days) 4. Molnupiravir (oral tx)

While supplies of therapeutics are expected to be limited, the overall aim in distribution and use should be to achieve the greatest [overall clinical benefit](#) to patients infected with COVID-19, avoid bias, and mitigate healthcare disparities. Clinicians are likely to find that they do not have adequate therapeutics supply for all eligible patients initially. This situation will be challenging for patients and family members, clinicians, and hospital staff. Use of multidisciplinary evidence-based clinical prioritization and [NIH treatment guidelines](#) are recommended.

[PAXLOVID EUA](#)
[PAXLOVID EUA FAQ](#)
[PAXLOVID PATIENT AND CAREGIVER FACTSHEET](#)
[FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE](#)
[AUTHORIZATION FOR PAXLOVID \(fda.gov\)](#)

[MOLNUPIRAVIR EUA](#)
[MOLNUPIRAVIR EUA FAQ](#)
[MOLNUPIRAVIR PATIENT AND CAREGIVER FACTSHEET](#)
[FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR MOLNUPIRAVIR](#)

[Provider Therapeutics Locator](#)